(Source: Datamonitor)
PAREXEL International Corporation, a biopharmaceutical company, has integrated its commercialization services to help clients maximize regional and global market access opportunities.
These solutions align reimbursement strategies with clinical development to gather the precise data required to demonstrate product value.
The PAREXEL commercialization services support the evolving needs of Health Economics and Outcomes Research (HEOR), Medical Affairs, Marketing, Reimbursement, and Managed Markets functions at biopharmaceutical company organizations. Clients benefit from the access PAREXEL has to a global network of Key Opinion Leaders (KOLs), as well as its database of global clinical trial experience, to assist in the development of effective commercialization strategies, the company said.
PAREXEL commercialization services include: Commercialization, reimbursement and market access strategy; Payer communications; Publication strategy; Global value and Academy of Managed Care Pharmacy (AMCP) dossier development; and Health outcomes analysis and economic modeling.
"More than ever our clients are faced with the acute need to prove that their products demonstrate value, in addition to safety and efficacy. Biopharmaceutical companies need to address commercialization goals as early as possible to develop products and acquire the right data to receive reimbursement approval in the most efficient way," said Gadi Saarony, Corporate vice president and Worldwide Head, PAREXEL Consulting and Medical Communications Services.
A service of YellowBrix, Inc.